You are here
Buz Investors DEA Schedules Insys Therapeutics’ Syndros Insys Therapeutics, Inc. (INSY) ("Insys" or the “Company") today announced that the Drug Enforcement Agency (“DEA”) has issued an interim final rule that would result in Syndros™ (dronabinol oral solution) being placed in Schedule II Market Trends 

$INSY DEA Schedules Syndros (dronabinol oral solution) as Schedule II Drug

DEA Schedules Insys Therapeutics’ Syndros (dronabinol oral solution) as Schedule II Drug Buz Investors DEA Schedules Insys Therapeutics’ Syndros  Insys Therapeutics, Inc. (INSY) (“Insys” or the “Company”) today announced that the Drug Enforcement Agency (“DEA”) has issued an interim final rule that would result in Syndros™ (dronabinol oral solution) being placed in Schedule II of the Controlled Substances Act. On July 1, 2016, the Food and Drug Administration (“FDA”) approved the New Drug Application for Syndros. Dr. Santosh Vetticaden, Ph.D., M.D., Interim CEO, and Chief Medical Officer, stated, “Insys is…

Read More
Minecoin Completes First Stage of ICO Ahead of Schedule Bitcoin News 

Minecoin Completes First Stage of ICO Ahead of Schedule

Minecoin Completes First Stage of ICO Ahead of Schedule MinexSystems, creator of Minecoin cryptocurrency has announced the completion of ICO’s first stage much before the scheduled date. Minecoin December 16, 2016, Kyiv, Ukraine – MinexSystems has successfully completed the first stage of its ICO, thanks to a commercial bank that acquired rest of the minecoin cryptocurrency. The bank’s participation has allowed MinexSystems to complete the ICO ahead of schedule. During the talks between MinexSystems and commercial banks’ representatives, which were conducted within the last 2 months (according to the terms of…

Read More